Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
R Du, C Huang, K Liu, X Li, Z Dong - Molecular cancer, 2021 - Springer
Aurora kinase A (AURKA) belongs to the family of serine/threonine kinases, whose
activation is necessary for cell division processes via regulation of mitosis. AURKA shows …
activation is necessary for cell division processes via regulation of mitosis. AURKA shows …
Cell cycle proteins as promising targets in cancer therapy
T Otto, P Sicinski - Nature Reviews Cancer, 2017 - nature.com
Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
B Coiffier, C Sarkozy - Hematology 2014, the American Society …, 2016 - ashpublications.org
Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …
Aurora kinase inhibitors: current status and outlook
V Bavetsias, S Linardopoulos - Frontiers in oncology, 2015 - frontiersin.org
The Aurora kinase family comprises of cell cycle-regulated serine/threonine kinases
important for mitosis. Their activity and protein expression are cell cycle regulated, peaking …
important for mitosis. Their activity and protein expression are cell cycle regulated, peaking …
Aurora‐A kinase: a potent oncogene and target for cancer therapy
M Yan, C Wang, B He, M Yang, M Tong… - Medicinal research …, 2016 - Wiley Online Library
The Aurora kinase family is comprised of three serine/threonine kinases, Aurora‐A, Aurora‐
B, and Aurora‐C. Among these, Aurora‐A and Aurora‐B play central roles in mitosis …
B, and Aurora‐C. Among these, Aurora‐A and Aurora‐B play central roles in mitosis …
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and …
B Melichar, A Adenis, AC Lockhart, J Bennouna… - The Lancet …, 2015 - thelancet.com
Background Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. We
aimed to investigate the safety and activity of single-agent alisertib in patients with …
aimed to investigate the safety and activity of single-agent alisertib in patients with …
Evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial
Importance Aurora A kinase (AURKA) activation, related in part toAURKAamplification and
variants, is associated with downregulation of estrogen receptor (ER) α expression …
variants, is associated with downregulation of estrogen receptor (ER) α expression …
Transformed follicular non-Hodgkin lymphoma
C Casulo, WR Burack… - Blood, The Journal of the …, 2015 - ashpublications.org
Histologic transformation of follicular lymphoma to an aggressive non-Hodgkin lymphoma is
a critical biologic event with profound implications on the natural history of this otherwise …
a critical biologic event with profound implications on the natural history of this otherwise …
Randomized phase III study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma
OA O'Connor, M Özcan, ED Jacobsen… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE The aim of this open-label, first-in-setting, randomized phase III trial was to
evaluate the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with …
evaluate the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with …
BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis
Cancer therapies trigger diverse cellular responses, ranging from apoptotic death to
acquisition of persistent therapy-refractory states such as senescence. Tipping the balance …
acquisition of persistent therapy-refractory states such as senescence. Tipping the balance …